MedX Health Corp. announced a Memorandum of Understanding for the launch of a new commercialization pilot project with PharmaChoice Canada, with more than 1000 independent pharmacy owners and operators across its PharmaChoice and RxHealthMed brands. The Pilot Project is scheduled to commence in May 2023 and to run for a three-month assessment period.

Initially, the Pilot Project will be conducted at twenty (20) PharmaChoice locations in four Provinces: British Columbia, Ontario, Nova Scotia and Newfoundland. Depending on assessments, success and demand, the Pilot Project may be expanded up to fifty (50) locations across Canada. Upon successful completion of the Pilot Project, PharmaChoice and MedX anticipate that access to MedX's teledermatology screening service will be rolled out across the entire PharmaChoice chain of pharmacies.

PharmaChoice will pilot MedX's cloud-based DermSecure technology platform that allows patients quick and easy access to a qualified dermatologist. A single scan by a MedX SIAscope captures five high-resolution images of suspicious moles, lesions and skin conditions, including four spectrophotometric images taken 2mm below the skin's surface. The MedX SIAscope, coupled with its HD Camera, enables a technician in a pharmacy consulting room to take a clinical image of a patient's suspicious mole or lesion which, together with the patient's medical history, is uploaded onto the DermSecure platform and assessed by a dermatologist within 72 hours, thus enabling a rapid response when the need arises.